South Korea-based Samyang Holdings Biopharm Group has secured a partnership with Hangzhou-based Yxintent, a specialist in medical devices and aesthetics, for its dermal filler product Lafullen. The partnership deal grants Yxintent the development and commercialization rights to Lafullen in China, marking a significant step for Samyang as it expands into the Chinese market.
Lafullen: A Biodegradable Dermal Filler with Long-Lasting Effects
Lafullen is a dermal filler made from polycaprolactone (PCL), a biodegradable polymer substance used to smooth facial wrinkles and lines, with a reported duration of up to two years. The product received its initial approval in South Korea in 2021 and has since been gaining traction in global aesthetics markets.
Strategic Market Entry and Expansion Plans
Samyang aims to capitalize on China’s rapidly growing market by supplying approximately KRW 100 billion (USD 76.8 million) worth of Lafullen product over the next five years. This strategic move into China is part of Samyang’s broader expansion into global markets. In April, Lafullen gained approval in Indonesia, and the company is currently in discussions for partnerships to enter other South-East Asian markets as well as Latin America.-Fineline Info & Tech
